Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07410624 · ClinicalTrials.gov registry record
Augmented Renal Clearance in Neurocritical Care
A clinical trial of Ischemic Stroke and Intracerebral Hemorrhage, sponsored by University of Alberta.
- Recruiting
- Registry status
- 512
- Enrollment target
- 3
- Study locations
NCT07410624 is a study of Ischemic Stroke and Intracerebral Hemorrhage that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 512 participants, below the 1,456-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07410624, a study of Ischemic Stroke and Intracerebral Hemorrhage, is actively recruiting participants, sponsored by University of Alberta.
- RECRUITING
- Registry status
- 512 participants
- Enrollment target
- 3
- Study locations
Study Summary
Stroke, severe brain injury, uncontrolled seizures and brain infections are the most common life-threatening neurological illnesses in the world with an estimated combined annual hospital management cost of up to 44 billion dollars. Seizures and infections are common complications following acute neurological illnesses and contribute significantly to poor outcomes if not promptly treated with appropriately dosed anti-seizure medications and antibiotics, respectively. Limited research suggested that many of those patients present with a phenomenon called augmented renal clearance (ARC) or, in other words, enhanced kidney function. ARC may have a significant influence on how medications are removed from the body potentially resulting in insufficient doses and treatment failure. Therefore, patients with ARC require higher medication doses; however, ARC is largely undetected using kidney assessment methods currently used in practice. In addition, it is not clear how medications should be dosed in those with ARC. The majority of ARC research has not focused on patients with life-threatening neurological illnesses. Thus, clinicians are likely under-dosing vital medications in those patients, and completely unaware. There is an immediate need to address the gap in knowledge. Therefore, this research aims to characterize the phenomenon of ARC in patients with life-threatening neurological illnesses through identifying the frequency, duration, contributing factors and clinical impact of ARC. Adult patients admitted to the neurosciences intensive care unit for life-threatening neurological illnesses will be enrolled in the study. Urine and blood samples wil be collected from participants to determine the presence of ARC and identify its contributing factors. In addition, blood samples will be collected from participants treated with select antibiotics and anti-seizure medications to determine their concentration and propose dose adjustment in those with ARC. This research is
Conditions Studied
Study Locations (3)
Kentucky
- UK HealthCare - Lexington
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Alberta
- University of Alberta Hospital - Edmonton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2026-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07410624
The ClinicalTrials.gov registry entry for NCT07410624 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 512 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,456-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (65% lower). The listed sponsor is University of Alberta, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Ischemic Stroke appearing as the primary indexed condition, and to 0 interventions.
NCT07410624 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kentucky, Ohio, Alberta.
Frequently Asked Questions
What is clinical trial NCT07410624 about?
NCT07410624 is a clinical study titled "Augmented Renal Clearance in Neurocritical Care". Stroke, severe brain injury, uncontrolled seizures and brain infections are the most common life-threatening neurological illnesses in the world with an estimated combined annual hospital management cost of up to 44 billion dollars. Seizures and infections are common complications following acute ne...
What is the current status of trial NCT07410624?
This trial is currently recruiting. The enrollment target is 512 participants. The study started on 2021-10-01. Estimated completion is 2026-09-30.
What conditions does trial NCT07410624 study?
This clinical trial studies the following conditions: Ischemic Stroke, Intracerebral Hemorrhage, TBI (Traumatic Brain Injury), Status Epilepticus, Subarachnoid Hemorrhage, Aneurysmal.
Who is sponsoring clinical trial NCT07410624?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07410624 being conducted?
This trial has 3 study locations across Kentucky, Ohio, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Of Vagus Nerve Stimulation (VNS) With Mobility Training For Gait Recovery After Chronic Ischemic Stroke
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Transitions of Care for Stroke Patients
RECRUITING
-
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
RECRUITING · NA
-
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
RECRUITING · NA
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.